Adele GLP-1 Before and After: A Photographic and Clinical Analysis

What the Photographic Timeline Actually Shows

Photographic evidence places the most visible body-composition change between early 2019 and October 2020, when Adele posted a birthday photo that drew widespread public attention. That is roughly a 20-month window. Media estimates of her starting weight (commonly cited in the 220 to 230 lb range at the 2019 Brit Awards) come from tabloid and entertainment coverage, not a medical record, and should be read as approximate.

By her May 2020 birthday photo, visible facial and upper-body slimming was already apparent. Her October 2020 "SNL" hosting appearance made the transformation broadly public.

What can and cannot be judged from photographs

A commonly discussed feature of her photos is that the loss looks concentrated in the face and midsection more than the limbs. Lifestyle-only weight loss typically reduces subcutaneous and visceral fat in roughly similar proportion, while some GLP-1 receptor agonist trials have examined preferential effects on visceral fat specifically. That distinction matters clinically, but it cannot be confirmed from a photograph. Body-composition changes require imaging (DEXA or similar) to establish, and no such data exists in the public record for Adele. The most that can honestly be said is that her visible pattern is consistent with either aggressive caloric restriction combined with resistance training, or that same combination further augmented by a GLP-1 drug. Photographs alone cannot distinguish between the two.

Rapid, large-magnitude weight loss (above roughly 15% of body weight) commonly produces visible facial volume changes within the first six months, and a longer, slower loss trajectory generally produces less loose facial skin than a fast crash-diet-style cut. The absence of visible facial ptosis in Adele's later photos is sometimes cited as evidence for a slower, sustained loss, which is plausible but, again, not something a photograph can prove.

The Sirtuin Diet: What It Is and What the Evidence Supports

Adele's team has credited the "Sirtfood Diet," developed by nutritionists Aidan Goggins and Glen Matten. The diet is built around foods believed to activate sirtuins, a family of seven NAD-dependent enzymes (SIRT1 through SIRT7) involved in metabolic regulation and cellular stress response [2].

Phase one: an aggressive caloric restriction window

The original protocol restricts intake to roughly 1,000 kcal/day for the first three days, then 1,500 kcal/day for four more days, before easing into a less restrictive maintenance phase. Emphasized foods include kale, red wine in moderation, dark chocolate, green tea, and buckwheat, chosen for polyphenols such as quercetin, resveratrol, and luteolin, which activate SIRT1 in laboratory studies [3].

The important clinical caveat is that most of the evidence for dietary sirtuin activation comes from in vitro or animal models. A 2020 review in Nutrients found insufficient human randomized-trial evidence to confirm that sirtuin activation from food adds fat loss beyond what the caloric deficit itself produces [4]. In plain terms, the early, rapid weight loss reported by people starting this diet is largely glycogen depletion and water loss driven by a steep calorie deficit, not a distinct metabolic effect of the specific foods.

Later phases

Weeks two and three allow three sirtuin-rich meals per day plus a green juice, targeting roughly 1,500 kcal/day, before an unrestricted maintenance phase. As a sustained eating pattern, this is nutritionally reasonable and overlaps considerably with the Mediterranean diet, which has stronger long-term evidence: the PREDIMED trial (N=7,447) found roughly a 30% relative reduction in major cardiovascular events compared with a low-fat control diet [5]. That trial was conducted in an older, cardiovascular-risk population in Spain, and its cardiovascular endpoint is not the same thing as weight loss, so it supports the diet's general healthfulness rather than the specific weight-loss numbers attributed to Adele.

GLP-1 Receptor Agonists: Clinical Benchmarks for Comparison

Adele has not confirmed GLP-1 use. What follows is a comparison of published trial outcomes against her reported timeline, offered as context, not as a claim about what she did.

STEP-1 and semaglutide 2.4 mg

STEP-1, published in the New England Journal of Medicine in 2021 (N=1,961), is the primary trial for semaglutide 2.4 mg (Wegovy) in adults without diabetes. Participants lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo [6]. Applied to a starting weight of 225 lbs, that is roughly 33.5 lbs, not 100 lbs. Reaching a 100-lb loss from semaglutide alone at standard dosing would require a starting weight above 650 lbs, which is not consistent with Adele's reported baseline. That arithmetic makes a single-drug semaglutide explanation for her full reported transformation implausible without a substantial concurrent lifestyle change.

On June 4, 2021, the FDA granted approval for semaglutide 2.4 mg in adults seeking chronic weight management who have a BMI of 30 or higher, or 27 or higher alongside at least one weight-related condition [7]. This regulatory milestone occurred following the most publicly visible period of her weight loss journey. Throughout most of the documented period of her changes, liraglutide 3.0 mg (Saxenda) remained the sole GLP-1 medication approved by the FDA for weight management, having received clearance in December 2014 [8].

Liraglutide 3.0 mg as the available option during her timeline

The SCALE Obesity and Prediabetes trial (N=3,731) found a mean 8.4% weight loss at 56 weeks versus 2.8% with placebo [9]. For a 225-lb person, that is roughly 18.9 lbs. As with semaglutide, lifestyle change would need to account for most of any reported 100-lb total.

Tirzepatide is not relevant to this timeline

Tirzepatide (marketed as Zepbound for weight management) was approved after Adele's transformation was largely complete. SURMOUNT-1 (N=2,539) showed 20.9% mean weight loss at 72 weeks with the 15 mg dose [10]. It has no plausible role in a 2019-to-2021 timeline.

Exercise and Body Composition

Adele's trainer, Pete Geracimo, has described a program combining circuit weight training, cardio intervals, and Pilates several days a week. Exercise-only interventions typically produce modest weight loss on their own (roughly 2 to 4% of body weight over a year), but resistance training combined with caloric restriction helps preserve lean mass, which changes how a given amount of weight loss looks visually. A person who loses fat while maintaining or slightly gaining muscle can look substantially more transformed than the net number on a scale would suggest.

One relevant line of exercise research compared aerobic and resistance training's effects on visceral fat, liver enzymes, and insulin resistance in overweight adults and found that training modality affects these outcomes differently even at similar amounts of weight loss [12]. Separately, resistance training has been studied for its effects on cardiometabolic markers such as glucose and lipids in older adults [11]; that population is meaningfully different from a woman in her early 30s, so applying those specific findings to Adele's case is an extrapolation, not a direct match.

A Framework for Evaluating Rate, Distribution, and Timeline

When evaluating any public figure's reported transformation, a few variables are more useful than others.

Rate of loss. Loss exceeding roughly 1% of body weight per week, sustained beyond about eight weeks, is unusual without medical intervention, severe caloric restriction, or both. Adele's reported rate works out to roughly 0.5% of body weight per week for a 225-lb starting point, which is achievable through aggressive lifestyle change alone, though it sits at the upper end of what is typically sustainable without appetite-suppressing medication.

Distribution. A pattern of preferential truncal and facial slimming with more preserved limb muscle can suggest either GLP-1 pharmacotherapy or a high volume of resistance training during caloric restriction. Photographs alone cannot separate these two explanations.

Timeline relative to drug availability. Liraglutide 3.0 mg was available throughout Adele's reported transformation window. Semaglutide 2.4 mg was not approved until after the most visible part of it had already occurred.

Public corroboration. There is no statement from Adele, a physician, or a representative confirming GLP-1 use. Her own public statements credit diet and exercise exclusively.

None of this confirms or rules out medication use. It establishes what the published trials show and where a public figure's documented transformation is, or is not, consistent with that evidence.

Evidence and Transferability Map: Applying Trial Data to an Unconfirmed Individual Case

Every number in this article comes from a clinical trial population that is different, in important ways, from any specific individual, including a public figure whose health status has never been disclosed. The table below separates what trials actually measured from what would need to be extrapolated, verified by a specialist, or monitored if a real patient were pursuing a comparable protocol.

The pattern across this table is consistent: trial percentages are real, but applying them to any one person, famous or not, always involves some degree of extrapolation. That is true whether the person is confirmed to be using a GLP-1 drug or not.

Endocrine Context: Why Individual Response Varies

GLP-1 receptor agonists work by mimicking endogenous GLP-1, a hormone released from L-cells in the distal small intestine and colon after eating. It stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and signals satiety through vagal and hypothalamic pathways [13].

Individual response to either dietary restriction or GLP-1 therapy varies with baseline insulin sensitivity, resting metabolic rate, gut microbiome composition, and genetic factors. The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity notes that the degree of weight loss varies considerably between individuals, and that not everyone achieves clinically meaningful weight loss with a given medication [14]. That variability is one reason a 100-lb loss from lifestyle change alone, while uncommon, is not biologically implausible for every individual.

What a GLP-1 Evaluation and Protocol Generally Involves

This section describes how obesity medicine follows FDA labeling in general terms. It is not guidance for any individual reader and does not substitute for an in-person medical evaluation.

Titration

The FDA-approved schedule for semaglutide 2.4 mg starts at 0.25 mg subcutaneously once weekly, escalating in 0.25 mg increments roughly every four weeks up to the 2.4 mg maintenance dose by around week 16 to 20 [7]. This gradual increase is intended to reduce gastrointestinal side effects. Nausea was reported in 44.2% of the semaglutide group in STEP-1 versus 16.0% with placebo [6].

Concurrent lifestyle counseling

STEP-1 paired the medication with a roughly 500 kcal/day dietary deficit and at least 150 minutes of moderate-intensity activity per week [6]. This is a meaningfully lower exercise volume than the multi-day, multi-modality circuit training Adele's trainer has described publicly, which is a further reason her documented routine, on its own, could account for substantial weight loss independent of any medication.

Monitoring and contraindications

Standard monitoring for GLP-1 therapy typically includes fasting glucose and HbA1c at baseline and periodically thereafter, a lipid panel, and attention to the class-level boxed warning regarding medullary thyroid carcinoma risk observed in rodent studies. A personal or family history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma is a contraindication under the FDA label [7]. A small increase in resting heart rate (roughly 1 to 2 bpm) was observed in STEP-1 [6]. None of this is a substitute for individualized dosing decisions made by a prescribing clinician who has reviewed a patient's full history.

On the "GLP-1 Rumor" Problem

Many outlets have stated Adele's GLP-1 use as fact without citing a physician, pharmacy record, or statement from her team. Meaningful weight loss without pharmacotherapy is documented in the literature: the CALERIE-2 trial (N=218) tested sustained 25% caloric restriction in non-obese adults over 24 months. The specific magnitude of weight loss most often quoted for that trial should be checked against its outcomes publication rather than assumed, since the reference most readily available for this article was a design and methodology paper rather than a results paper [15]. What can be said with more confidence is that sustained, substantial caloric restriction produces clinically meaningful weight loss even in people who do not start out obese, which is relevant background for evaluating any large reported loss.

Attributing a specific person's transformation to a specific drug without confirmation is speculation, not clinical assessment. This article does not conclude that Adele used a GLP-1 medication. It lays out what the published trials show, and where her publicly reported timeline is, or is not, consistent with that evidence. Obesity medicine specialty organizations have generally emphasized that obesity is a chronic condition best treated with individualized plans that may combine lifestyle, behavioral, pharmacological, and surgical approaches, rather than any single intervention in isolation [16]. Readers should treat that specific attribution cautiously, since the reference available for this statement should be verified against the original source document before publication.